Compare Viatris Inc (VTRS) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Viatris Inc trades at $17.5 (market cap $20.03B), while Vanguard Total International Stock Index Fund ETF trades at $84.58 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 33.2× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| VTRS | VXUS | |
|---|---|---|
Market Cap | $20.03B | $665.70B |
Volume | 14,109,977 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $18.27 | $88.41 |
52-Week Low | $9.74 | $72.17 |
Typical Hold Time | 57 Days | 55 Days |
Enterprise Value | $32.15B | — |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
VXUS, the Vanguard Total International Stock ETF, trades at $84.56, down 0.26% with a bearish technical signal. The ETF provides diversified exposure to international developed and emerging markets outside the US. Recent news highlights its role in portfolio diversification and institutional buying interest, though technical indicators show selling pressure across moving averages and oscillators.
The outlook for VXUS hinges on international market performance relative to US equities, with potential for long-term growth diversification. Risks include currency fluctuations and regional economic volatility. Institutional accumulation suggests confidence in international equity exposure as a strategic portfolio component.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
